BIOMAT Database Logo BIOMAT Database Logo

Preliminary screening of anticholinergic effect of new 1,3-dioxolane and 1,3,-dioxane derivatives. 1978

J Faff, and J Woliński, and J Bandolet, and E Widy-Tyszkiewicz, and Z Szreniawski

Some of the 28 investigated new derivatives show distinct anticholinergic activity. The greatest activity, that of 2-cyclohexyl-2-phenyl-5-piperidinodioxane-1,3 was greater than of the atropine sulfate.

UI MeSH Term Description Entries
D007928 Lethal Dose 50 The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population. LD50,Dose 50, Lethal
D008297 Male Males
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D009130 Muscle, Smooth Unstriated and unstriped muscle, one of the muscles of the internal organs, blood vessels, hair follicles, etc. Contractile elements are elongated, usually spindle-shaped cells with centrally located nuclei. Smooth muscle fibers are bound together into sheets or bundles by reticular fibers and frequently elastic nets are also abundant. (From Stedman, 25th ed) Muscle, Involuntary,Smooth Muscle,Involuntary Muscle,Involuntary Muscles,Muscles, Involuntary,Muscles, Smooth,Smooth Muscles
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D004146 Dioxanes Compounds that contain the structure 1,4-dioxane.
D004147 Dioxins A family of compounds that contain the 1,4-dioxin structure. Many specific dioxin derivatives are listed as CARCINOGENS; TERATOGENS; or MUTAGENS. Dioxin
D004148 Dioxolanes
D004149 Dioxoles
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug

Related Publications

J Faff, and J Woliński, and J Bandolet, and E Widy-Tyszkiewicz, and Z Szreniawski
New 1,3-dioxolane and 1,3-dioxane derivatives as effective modulators to overcome multidrug resistance.
March 2007, Bioorganic & medicinal chemistry,
J Faff, and J Woliński, and J Bandolet, and E Widy-Tyszkiewicz, and Z Szreniawski
[Search for anticholinergic agents. IV. Synthesis of 4-piperidinemethyl-1,3-dioxolane derivatives].
January 1977, Acta poloniae pharmaceutica,
J Faff, and J Woliński, and J Bandolet, and E Widy-Tyszkiewicz, and Z Szreniawski
[Hydrolytic stability of various 1,3-dioxolane, 1,3-oxathiolane and 1,3-dithiolane derivatives].
March 1975, Die Pharmazie,
J Faff, and J Woliński, and J Bandolet, and E Widy-Tyszkiewicz, and Z Szreniawski
1,3-dioxane derivatives of muscarinic activity.
December 1970, Il Farmaco; edizione scientifica,
J Faff, and J Woliński, and J Bandolet, and E Widy-Tyszkiewicz, and Z Szreniawski
A Comparative Study on the Combustion Chemistry of Two Bio-hybrid Fuels: 1,3-Dioxane and 1,3-Dioxolane.
January 2023, The journal of physical chemistry. A,
J Faff, and J Woliński, and J Bandolet, and E Widy-Tyszkiewicz, and Z Szreniawski
5-nitrofurfuryl derivatives of 1,3-dioxan and 1,3-dioxolane as antimicrobial agents.
January 1984, Pharmaceutica acta Helvetiae,
J Faff, and J Woliński, and J Bandolet, and E Widy-Tyszkiewicz, and Z Szreniawski
[The search for anticholinergic compounds. XXXVIII. Synthesis of 4-(2-aminoethylaminomethyl)-2-benzyl-2-phenyl-1,3-dioxolane derivatives].
January 1982, Acta poloniae pharmaceutica,
J Faff, and J Woliński, and J Bandolet, and E Widy-Tyszkiewicz, and Z Szreniawski
Synthesis of pyrazolone derivatives. XXIX. Synthesis of 1,3-dioxolane-indazole derivatives.
May 1977, Chemical & pharmaceutical bulletin,
J Faff, and J Woliński, and J Bandolet, and E Widy-Tyszkiewicz, and Z Szreniawski
Unusual dielectric response of 4-methyl-1,3-dioxolane derivatives.
November 2018, Physical chemistry chemical physics : PCCP,
J Faff, and J Woliński, and J Bandolet, and E Widy-Tyszkiewicz, and Z Szreniawski
[The search for anticholinergic compounds. XXXVII. Determination of the relation between the structure and pharmacological action of various 1,3-dioxolane derivatives].
January 1982, Acta poloniae pharmaceutica,
Copied contents to your clipboard!